Cardinal Health (CAH) is headquartered in Dublin, OH. The company is one of the world’s largest providers of healthcare services and products, operating across Pharmaceutical & Specialty Solutions, Global Medical Products & Distribution (GMPD), and Other growth businesses. The company serves nearly 90% of U.S. hospitals, delivers more than 43,000 pharmaceutical shipments daily, and manages a broad portfolio of medical, surgical, and laboratory products.
About This Page
Stockmark101.com is a free educational site focused on explaining how stocks and markets work. Company write-ups reflect general market commentary and publicly available information and are used to illustrate business fundamentals and market behavior — not personalized investment advice.
| Price | $215 | Catergory | Moderate | |
| Market Cap | $50.6B | Dividend | $2.04 | 0.94% |
| P/E Ratio | 30.97 | Analyst Avg | 1-Yr Target | $249 |
| Consensus EPS Estimate | 1Q | 2Q | 3Q | 4Q |
| 2027 | 2.70E | 2.78E | ||
| 2026 | 2.55A | 2.63A | 2.80E | 2.33E |
| 2025 | 1.88A | 1.93A | 2.35A | 2.08A |
*Aggressive/Moderate/Conservative labels describe broad business characteristics for educational purposes only. They are not risk ratings, investment guidance, or recommendations. A = Actual, E = Estimated. Market metrics such as beta, valuation multiples, and analyst estimates are widely referenced in financial research. Their relevance depends on an individual’s goals, time horizon, and risk tolerance. These figures are for informational purposes only and should not be interpreted as predictions or guidance.
Keys for Success
Total Addressable Market Opportunity: Cardinal Health operates in one of the largest and most resilient markets in healthcare: pharmaceutical distribution and medical products. The U.S. pharmaceutical wholesale and distribution market is estimated at $844.2 billion in 2024 and is projected to grow at a 8.7% CAGR through 2034.
Strong Specialty and Branded Pharma Growth: Cardinal Health’s pharmaceutical segment continues to benefit from robust demand for branded and specialty drugs, particularly GLP-1 therapies for diabetes and obesity management. Excluding the OptumRx contract expiration, pharma revenue grew at double digits in the first half of fiscal 2026, supported by higher branded drug sales, oncology therapies, and biopharma solutions. Specialty pharmaceuticals—covering oncology, gastroenterology, rheumatology, and gene therapies—carry higher margins and long-term demand tailwinds as biologics gain share of overall spending.
GMPD Turnaround Strengthening Profitability: After years of pressure from inflation, supply chain disruption, and thin margins, Cardinal Health’s GMPD segment is showing tangible recovery. Revenue grew 3% in the first half of fiscal 2026, while segment profit turned positive, with the second quarter delivering a 106% growth in profit. Cost controls, supplier renegotiations, and automation investments are expected to further stabilize profitability.
At-Home Solutions and Other Growth Businesses: Cardinal Health’s Other segment, comprising at-Home Solutions, Nuclear & Precision Health Solutions, and OptiFreight Logistics, has become a key driver of growth, contributing 36% revenue growth and 55% profit growth in the first half of fiscal 2026. At-Home Solutions now directly serves more than five million patients, positioning CAH at the center of the growing shift toward home-based healthcare. OptiFreight continues to deliver cost-saving logistics solutions, and the Nuclear business benefits from rising demand for theranostics and diagnostic imaging.
Strategic Acquisitions Driving Long-Term Value: Cardinal Health has deployed more than $6 billion in acquisitions across specialty and home healthcare in the past two years, signaling a strategic pivot toward higher-margin adjacencies. These moves diversify Cardinal Health’s portfolio, reduce reliance on low-margin wholesale, and deepen integration with providers and biopharma manufacturers.
Keys for Concern
Cardinal Health’s heavy reliance on large contracts exposes it to revenue volatility. The expiration of the OptumRx contract in fiscal 2025 led to a 3% decline in pharma revenue, erasing billions in top-line contribution. Competitors McKesson and Cencora remain formidable rivals. Cardinal Health remains vulnerable to inflationary pressures. Cardinal Health benefited from elevated COVID-19-related product and vaccine distribution revenue during fiscal 2021 to fiscal 2023. However, the tapering demand for vaccines and associated supplies such as PPE and syringes has become a headwind.
Mark Notes
Cardinal Health is a leading health care company benefiting from demographic shifts and an aging population. Carinal Health is driving growth through specialty pharma, at-home care, and GMPD turnaround, supported by strategic acquisitions that expand margins and diversify beyond low-margin distribution.
New to investing? These explanations may help:
Growth vs. Value: Why Some Stocks Move So Differently
This article is for general informational and educational purposes only. It is not intended as financial advice, investment guidance, or a recommendation to buy or sell any security. The content reflects publicly available information and broad market commentary. Readers should conduct their own research and consult a licensed financial professional before making investment decisions.